Alemtuzumab
- BNF:
- 8.2.3
- Status:
- Red
- Decision Date:
- June 2014
Comments
RED
- NICE TA312: for treating highly active relapsing remitting multiple sclerosis. NHSE commissioned. (Decision date - June 2014).
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
search again